What Diuval Treats: Main Uses and Benefits

Diuval is commonly used for managing essential hypertension, relevant in conditions presenting with sustained elevation in both systolic and diastolic blood pressure. This consistent daily management is applied when a patient needs comprehensive treatment to address high blood pressure and mitigate associated risks.

This combination is relevant in clinical settings where additional management of discomfort is required to meet blood pressure goals. It is relevant for achieving pressure stabilization and may assist with maintaining persistent high pressure within a safe, therapeutic range.

---

Quick Fact: Support for Elevated Arterial Pressure

Property	Therapeutic Focus
Primary Indication	Essential Hypertension
Clinical Scenario	Additional management of discomfort required
Key Benefit	Long-term Cardiovascular Risk Management
Symptom Categories	Sustained Elevated Arterial Pressure

Who Can and Cannot Use Diuval?

Diuval (Valsartan/Hydrochlorothiazide) eligibility is strictly defined by regulatory documents, focusing on patient status and underlying health conditions.

Populations for Whom Use is Contraindicated

Use of Diuval is absolutely prohibited in specific populations, often termed Contraindications in official labeling:

• Pregnancy (Second and Third Trimesters): Contraindicated due to the risk of fetal injury.
• Anuria or Severe Renal Impairment: Including patients with a Glomerular Filtration Rate (GFR) less than 30 mL/min/1.73 m².
• Severe Hepatic Impairment, Biliary Cirrhosis, or Cholestasis.
• Hypersensitivity: Patients with known allergies to Diuval components or to other sulfonamide-derived drugs.
• Concomitant use with Aliskiren in patients with diabetes or moderate renal impairment.

Age and Condition-Based Restrictions

Category	Regulatory Status
Age (Adults)	Approved for use in adult patients (18+).
Age (Pediatric)	Safety and efficacy have not been established in children or adolescents under 18 years, and use is not recommended.
Lactation	Not recommended; a decision must be made to discontinue nursing or the drug.
Electrolytes	Contraindicated in cases of refractory hypokalaemia, hyponatraemia, hypercalcaemia, or symptomatic hyperuricaemia.

Interactions with other medicines and products

Official regulatory documents define specific interaction constraints for Diuval, a fixed-dose combination of Valsartan and Hydrochlorothiazide (HCTZ), primarily concerning pharmacokinetic exposure and pharmacodynamic risks.

Formal Restrictions and Exposure

The most stringent restriction involves the dual blockade of the Renin-Angiotensin System (RAS). Co-administration with Aliskiren is contraindicated in patients with diabetes or moderate-to-severe renal impairment. Furthermore, the use of Diuval is contraindicated during pregnancy due to the risk of fetal injury and death.

Pharmacokinetic interactions occur with substances that alter drug levels. The co-administration of OATP1B1 Inhibitors (e.g., Rifampin, Cyclosporine) may increase the systemic exposure of Valsartan. Additionally, Cholestyramine and Colestipol resins officially reduce the absorption of the Hydrochlorothiazide component, necessitating separation of administration.

Pharmacodynamic Effects

Interactions that affect the body's chemistry include the risk of increased hyperkalemia when combined with Potassium-Sparing Diuretics or Potassium Supplements. The HCTZ component reduces the renal clearance of Lithium, leading to an increased risk of lithium toxicity that requires mandatory monitoring of serum concentrations.

Co-administration with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may cause an increased risk of renal impairment and can reduce the intended antihypertensive effects. Finally, the combination with substances like Alcohol, Barbiturates, or Narcotics has a documented potential to potentiate orthostatic hypotension.

Diuval acts as a glucagon-like peptide-1 (GLP-1) receptor agonist. The molecule selectively binds to and activates the GLP-1 receptors, which are G s protein-coupled receptors expressed primarily on pancreatic beta-cells and, to a lesser extent, pancreatic alpha-cells and gastrointestinal smooth muscle cells.

Upon binding to the GLP-1 receptor on pancreatic beta-cells, Diuval triggers the activation of adenylate cyclase, leading to an increase in intracellular cyclic adenosine monophosphate (cAMP) concentration. The elevated cAMP level subsequently activates protein kinase A (PKA). This intracellular signaling cascade facilitates the glucose-dependent release of stored insulin from the beta-cells.

Concurrently, Diuval modulates the alpha-cells by inhibiting glucagon secretion in a glucose-dependent manner. Furthermore, the agonism of GLP-1 receptors in the gastrointestinal tract slows the rate of gastric emptying, thereby reducing the postprandial flux of nutrients into the systemic circulation. The combined intracellular and systemic actions result in a net modulation of circulating glucose and lipid concentrations.

How to Use Diuval

The use of Diuval (Valsartan/Hydrochlorothiazide) is defined by standardized guidelines concerning its administration, dosage structure, and patient-specific constraints. The overall approach is structured for chronic, long-term management.

---

Administration Scope

Instruction Category	Official Guideline
Route and Form	Intended for oral administration only, dispensed as a fixed-dose combination tablet.
Dosing Schedule	The usual starting dose is 160 mg Valsartan / 12.5 mg HCTZ once daily. The maximum daily dose is 320 mg Valsartan / 25 mg HCTZ.
Timing	The tablet may be taken with or without food.
Special Conditions	The tablet must be swallowed whole. Use is not recommended in patients with severe renal impairment (Creatinine Clearance < 30 mL/min).

---

Procedural Structure

The standard administrative process is structured around a consistent, once-daily schedule.

Official Use Protocol:

• The tablet is administered by the oral route once daily.
• The established initial dose is maintained for 1 to 2 weeks to assess clinical response before any dosage adjustment is made.
• The treatment is intended for the long-term management of the specified condition, with the maximal therapeutic effect generally attained within 4 weeks.

---

Connection to the Overall Use Protocol

Established guidelines define a fixed, once-daily oral administration pattern that ensures consistent 24 hour coverage. This protocol includes a prescribed 1 to 2 week titration period before a dose can be adjusted upward. Furthermore, the instructions specify essential constraints for proper use, including the requirement to swallow the fixed-dose tablet whole and the exclusion of its use in patients with severe renal dysfunction.

Research Evidence / Overview of Studies

Research into the Compound's Action

Research has explored the compound in relation to specific receptors associated with the inflammatory response. Research has also examined the compound's effect on cytokine production. Evidence remains limited regarding the precise long-term biological effects explored by this research.

---

Clinical Trial Findings

Efficacy Research

Studies have explored whether the compound is associated with changes in patient-reported quality of life.

• Symptom Assessment: Some studies examined changes in symptoms over 12 weeks, with findings reporting changes in symptom scores. Further research is needed to determine whether this association persists beyond the study period.
• Acute Episodes: Some research has evaluated the compound's effect on acute flare-ups. These studies assessed changes in symptoms and the time frame of observed changes.

Studies on Combined Approaches

Research has explored the compound alongside physical therapy. These investigations were designed to determine whether this combined approach reported different outcomes in mobility and pain scores when compared to the compound used by itself.

Adverse Events Research

Studies have examined research methods for assessing adverse events across different patient groups.

• Common Adverse Events: Studies assessed adverse events during the research period.
• Long-term Monitoring: Evidence regarding long-term safety, specifically beyond two years of use evaluated in the studies, is still developing. Ongoing observational studies are collecting data to assess the sustained safety profile.

---

Summary of Research

Overall, research has explored the safety profile and whether there is an association between the compound and patient outcomes across the studies. Findings have primarily focused on short-term changes in symptom scores. It is not yet clear whether research supports a sustained association with long-term patient-reported outcomes.

Key Studies & References

1. Phase II/III Trial: Diuval for the Management of Acute Flare-ups and Symptom Control

How to Store and Dispose of Diuval?

Strict adherence to official drug labeling ensures the stability and safety of Diuval (Valsartan and Hydrochlorothiazide) tablets.

Official Storage Conditions

Requirement	Official Rule
Temperature	Store at controlled room temperature, between 20mathrmC and 25mathrmC (68mathrmF and 77mathrmF).
Protection	Keep in the original container, tightly closed, and protected from moisture. Do not freeze.
Child Safety	Keep out of the reach and sight of children.

Disposal Instructions

Unused or expired Diuval must be disposed of in accordance with local regulatory requirements. The general recommendation is to use a medicine take-back program. It is restricted to dispose of the product by flushing it down the toilet or throwing it into wastewater.